Biocon Limited Latest Updates

Commercial Launches & Product ApprovalsU.S. Denosumab Launch: On April 7, 2026, Biocon announced the commercial launch of Bosaya™ and Aukelso™ (denosumab biosimilars) in the United States. These are interchangeable with Amgen’s Prolia® and Xgeva® and target osteoporosis and cancer-related bone complications. GLP-1 Portfolio Expansion: Biocon received U.S. FDA approval for its generic Liraglutide injection (gVictoza®) on March 12, 2026, and gSaxenda® on February 24, 2026. This strengthens their position in the high-demand diabetes and weight management market. Diabetes Portfolio: In April 2026, the company secured U.S. FDA approval for Dapagliflozin tablets (5 mg and 10 mg) to treat type 2 diabetes and reduce heart failure hospitalization risks. International Approvals: Health Canada granted approval for denosumab biosimilars (Bosaya™ and Vevzuo™) in April 2026, expanding the company's footprint in North America. Corporate & Strategic Developments Leadership Transition: Effective April 1, 2026, Shreehas Tambe took over as CEO & Managing Director of Biocon Limited, succeeding Siddharth Mittal. Kedar Upadhye was appointed as the Group CFO. Fundraising & Debt: Biocon concluded a major equity fundraise of approximately ₹4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP) in January 2026 to strengthen its balance sheet and reduce debt. Credit Upgrades: In February 2026, S&P Global upgraded Biocon Biologics' credit rating to 'BB+' with a 'Stable' outlook, reflecting improved financial stability. Financial Performance (Q3 FY26) Revenue Growth: Consolidated revenue for the quarter ended December 31, 2025, rose 11% YoY to ₹4,290 crore. Operating revenue specifically grew 9% to ₹4,173 crore. Profitability: Reported Net Profit surged by 475% YoY to ₹144 crore. EBITDA stood at ₹951 crore (up 21%), with a margin of 22%